Position in EVMN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,073,729
+$4,960,929 QoQ
Shares Held
457,015
+603.1% QoQ
Ownership
1.26%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#19
of 105 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EVMN Over Time
Shares Held
Position Value (USD)
Derivatives in EVMN
reported options exposure · as of Jun 30, 2026CallValue
$2,259,300
CallShares
170,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Balyasny Asset Management L.P. holds $2,350,910,046 across 177 Biotechnology names. EVMN ranks #81 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
1,665,102 | $221,008,988 | |
| 2 | INSM |
INSMED Inc
|
1,326,430 | $141,423,966 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,230,052 | $91,614,272 | |
| 4 | ABVX |
Abivax S.A.
|
603,840 | $80,467,718 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
145,005 | $72,028,333 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
2,016,379 | $63,032,007 | |
| 7 | CYTK |
Cytokinetics Inc
|
711,676 | $60,627,678 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
1,054,613 | $60,344,955 |
All Filings in EVMN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,259,300 | 170,000 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $6,073,729 | 457,015 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $1,112,800 | 65,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||